Updated Jul 16, 2026
Thunen Shelley B has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $727K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | AEON | AEON Biopharma, Inc. | A — Grant or award | 222.7K | $0.00 | |
| 2025-04-14 | RXST | RxSight, Inc. | M — Option exercise | 7.8K | $4.34 | $34K |
| 2024-10-02 | RXST | RxSight, Inc. | S — Open-market sale [10b5-1] | 278 | $49.45 | $14K |
| 2024-10-02 | RXST | RxSight, Inc. | S — Open-market sale [10b5-1] | 9.5K | $48.69 | $464K |
| 2024-10-02 | RXST | RxSight, Inc. | S — Open-market sale [10b5-1] | 5.2K | $47.96 | $249K |
| 2024-10-02 | RXST | RxSight, Inc. | M — Option exercise [10b5-1] | 15.0K | $16.00 | $240K |
Thunen Shelley B is a corporate insider — currently tracked as Director of AEON Biopharma, Inc. (AEON). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($727K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Thunen Shelley B profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.